Sponsor Pipeline

Nanjing Bioheng Biotech Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
3
Recruiting
6
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-04 NCT07203404
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With…		 Enrollment increased: 84 -> 96 participants
Active Trials by Phase
Early Phase 1
5
Active Trials
NCT IDTitleConditionStatus
Early Phase 1
NCT06775912 Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases SLE Recruiting
NCT06548607 Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases SLE (Systemic Lupus) Recruiting
NCT07203404 A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With… SLE Recruiting
NCT07142161 A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T… Type 1 Diabetes Active, Not Recruiting
NCT07596680 CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases SLE - Systemic Lupus Erythematosus Not Yet Recruiting
Disease Areas
Lupus (SLE) (4) Scleroderma (3) Multiple Sclerosis (1) Type 1 Diabetes (1) Diabetes (1) Glioblastoma (1)
Get alerts when Nanjing Bioheng Biotech Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free